ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $2.93 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.